JP2022071060A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022071060A5 JP2022071060A5 JP2022030538A JP2022030538A JP2022071060A5 JP 2022071060 A5 JP2022071060 A5 JP 2022071060A5 JP 2022030538 A JP2022030538 A JP 2022030538A JP 2022030538 A JP2022030538 A JP 2022030538A JP 2022071060 A5 JP2022071060 A5 JP 2022071060A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- asparaginase
- polyalkylene oxide
- concentration
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960003272 asparaginase Drugs 0.000 claims 11
- 102100025573 1-alkyl-2-acetylglycerophosphocholine esterase Human genes 0.000 claims 6
- 108010024976 Asparaginase Proteins 0.000 claims 6
- 229920001281 polyalkylene Polymers 0.000 claims 6
- 239000002202 Polyethylene glycol Substances 0.000 claims 5
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 claims 5
- 229920001223 polyethylene glycol Polymers 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000007788 liquid Substances 0.000 claims 4
- 229920000233 poly(alkylene oxides) Polymers 0.000 claims 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims 2
- 230000008030 elimination Effects 0.000 claims 2
- 238000003379 elimination reaction Methods 0.000 claims 2
- 230000006698 induction Effects 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 238000012423 maintenance Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 229940045641 monobasic sodium phosphate Drugs 0.000 claims 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 2
- 235000019799 monosodium phosphate Nutrition 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 238000007596 consolidation process Methods 0.000 claims 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 238000011285 therapeutic regimen Methods 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025181444A JP2026016612A (ja) | 2016-06-01 | 2025-10-28 | ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法 |
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344252P | 2016-06-01 | 2016-06-01 | |
| US201662344256P | 2016-06-01 | 2016-06-01 | |
| US201662344249P | 2016-06-01 | 2016-06-01 | |
| US62/344,252 | 2016-06-01 | ||
| US62/344,256 | 2016-06-01 | ||
| US62/344,249 | 2016-06-01 | ||
| PCT/US2017/035461 WO2018017190A2 (en) | 2016-06-01 | 2017-06-01 | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same |
| JP2019515776A JP7109427B2 (ja) | 2016-06-01 | 2017-06-01 | ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515776A Division JP7109427B2 (ja) | 2016-06-01 | 2017-06-01 | ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025181444A Division JP2026016612A (ja) | 2016-06-01 | 2025-10-28 | ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022071060A JP2022071060A (ja) | 2022-05-13 |
| JP2022071060A5 true JP2022071060A5 (https=) | 2022-09-28 |
Family
ID=60992770
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515776A Active JP7109427B2 (ja) | 2016-06-01 | 2017-06-01 | ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法 |
| JP2022030538A Pending JP2022071060A (ja) | 2016-06-01 | 2022-03-01 | ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法 |
| JP2025181444A Pending JP2026016612A (ja) | 2016-06-01 | 2025-10-28 | ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019515776A Active JP7109427B2 (ja) | 2016-06-01 | 2017-06-01 | ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025181444A Pending JP2026016612A (ja) | 2016-06-01 | 2025-10-28 | ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法 |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US12343387B2 (https=) |
| EP (2) | EP3463308B2 (https=) |
| JP (3) | JP7109427B2 (https=) |
| KR (3) | KR102783452B1 (https=) |
| CN (1) | CN109640961B (https=) |
| AU (1) | AU2017299374B2 (https=) |
| BR (1) | BR112018074823B1 (https=) |
| CA (1) | CA3026070A1 (https=) |
| CL (1) | CL2018003418A1 (https=) |
| CO (1) | CO2018013753A2 (https=) |
| CY (1) | CY1124980T1 (https=) |
| DK (1) | DK3463308T4 (https=) |
| ES (1) | ES2905874T3 (https=) |
| FI (1) | FI3463308T4 (https=) |
| HR (1) | HRP20212027T4 (https=) |
| HU (1) | HUE057856T2 (https=) |
| IL (2) | IL263349B2 (https=) |
| LT (1) | LT3463308T (https=) |
| MX (2) | MX388814B (https=) |
| MY (1) | MY198474A (https=) |
| PH (1) | PH12018502540A1 (https=) |
| PL (1) | PL3463308T5 (https=) |
| PT (1) | PT3463308T (https=) |
| RS (1) | RS62979B2 (https=) |
| RU (1) | RU2758796C2 (https=) |
| SA (1) | SA518400557B1 (https=) |
| SG (1) | SG11201810685WA (https=) |
| SI (1) | SI3463308T2 (https=) |
| SM (1) | SMT202200049T1 (https=) |
| UA (1) | UA123020C2 (https=) |
| WO (1) | WO2018017190A2 (https=) |
| ZA (2) | ZA201807943B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200131231A1 (en) | 2017-02-17 | 2020-04-30 | Oxford University Innovation Limited | Cell penetrating peptides |
| GB201812980D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| GB201812972D0 (en) | 2018-08-09 | 2018-09-26 | Univ Oxford Innovation Ltd | Cell-penetrating peptides |
| WO2020089743A1 (en) | 2018-11-02 | 2020-05-07 | Cadila Healthcare Limited | Pharmaceutical composition of pegylated l-asparaginase |
| CN113453723A (zh) | 2018-12-07 | 2021-09-28 | 牛津大学科技创新有限公司 | 接头 |
| EP3867369A4 (en) * | 2018-12-24 | 2022-09-14 | Gennova Biopharmaceuticals Limited | LYOPHILIZED PEGASPARGASE COMPOSITION |
| CN117377494A (zh) * | 2021-04-06 | 2024-01-09 | 爵士制药爱尔兰有限公司 | L-天冬酰胺酶的调配物 |
| CN114392237B (zh) * | 2021-12-28 | 2024-02-02 | 上海允英生物医药科技有限公司 | 一种冻干病毒制剂及其制备方法 |
| CN119326875A (zh) * | 2024-12-23 | 2025-01-21 | 中国人民解放军总医院第三医学中心 | L-ASNase在制备治疗膀胱癌药物中的应用及试剂盒 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| DE2433883C2 (de) * | 1973-07-20 | 1986-03-27 | Research Corp., New York, N.Y. | Verwendung von physiologisch aktiven Polypeptiden |
| DE3279834D1 (en) * | 1981-12-31 | 1989-08-31 | Asta Pharma Ag | 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression |
| JPS58183626A (ja) | 1982-04-21 | 1983-10-26 | Nippon Oil Co Ltd | 白血病治療用ｌ−アスパラギナ−ゼ固定化剤 |
| US4729957A (en) | 1984-12-13 | 1988-03-08 | The United States Of America As Represented By The Department Of Health And Human Services | Process for manufacture of L-asparaginase from erwinia chrysanthemi |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5324844A (en) * | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| EP0470128B2 (en) * | 1989-04-19 | 2003-08-13 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| GB9017002D0 (en) | 1990-08-02 | 1990-09-19 | Health Lab Service Board | Improved method for the purification of erwina l-asparaginase |
| US5618710A (en) * | 1990-08-03 | 1997-04-08 | Vertex Pharmaceuticals, Inc. | Crosslinked enzyme crystals |
| TW197439B (https=) | 1991-04-04 | 1993-01-01 | Ueno Pharmaceutics Applic Res Co Ltd | |
| US5283253A (en) | 1991-09-23 | 1994-02-01 | Florida State University | Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them |
| WO1993010076A1 (en) | 1991-11-22 | 1993-05-27 | The University Of Mississippi | Synthesis and optical resolution of the taxol side chain and related compounds |
| US5200534A (en) | 1992-03-13 | 1993-04-06 | University Of Florida | Process for the preparation of taxol and 10-deacetyltaxol |
| JPH08500973A (ja) | 1992-05-21 | 1996-02-06 | ザ ペン ステイト リサーチ ファウンデーション | タキソール、関連タキサン及び他の新規な抗癌／抗ウイルス性化合物原料としてのイチイ培養組織 |
| US5274137A (en) | 1992-06-23 | 1993-12-28 | Nicolaou K C | Intermediates for preparation of taxols |
| US5294637A (en) | 1992-07-01 | 1994-03-15 | Bristol-Myers Squibb Company | Fluoro taxols |
| US5202448A (en) | 1992-08-14 | 1993-04-13 | Napro Biotherapeutics, Inc. | Processes of converting taxanes into baccatin III |
| CA2100808A1 (en) | 1992-10-01 | 1994-04-02 | Vittorio Farina | Deoxy paclitaxels |
| FR2696461B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent. |
| FR2696462B1 (fr) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
| FR2696463B1 (fr) | 1992-10-05 | 1994-11-25 | Rhone Poulenc Rorer Sa | Procédé d'obtention de la désacétyl-10 baccatine III. |
| FR2696464B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III. |
| FR2696458B1 (fr) | 1992-10-05 | 1994-11-10 | Rhone Poulenc Rorer Sa | Procédé de préparation de dérivés du taxane. |
| US5279949A (en) | 1992-12-07 | 1994-01-18 | Board Of Trustees Operating Michigan State University | Process for the isolation and purification of taxol and taxanes from Taxus spp |
| US6277828B1 (en) | 1993-08-20 | 2001-08-21 | Syntex (U.S.A.) Inc. | Pharmaceutical formulations of nerve growth factor |
| US5824701A (en) | 1993-10-20 | 1998-10-20 | Enzon, Inc. | Taxane-based prodrugs |
| US5415869A (en) | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
| US6087151A (en) | 1995-02-08 | 2000-07-11 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | DNA coding for mammalian L-asparaginase |
| WO1996033212A1 (fr) | 1995-04-21 | 1996-10-24 | Teikoku Hormone Mfg. Co., Ltd. | Nouveaux derives peptidiques |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| US6537547B1 (en) | 1996-06-07 | 2003-03-25 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Polypeptides having L-asparaginase activity |
| WO1998008833A1 (en) | 1996-08-26 | 1998-03-05 | Bristol-Myers Squibb Company | Sulfenamide taxane derivatives |
| EP0961619A4 (en) | 1996-09-27 | 2001-09-26 | Bristol Myers Squibb Co | HYDROLYSABLE DRUGS FOR THE RELEASE OF ANTI-CANCER DRUGS IN METASTATIC CELLS |
| AU4966597A (en) | 1996-11-19 | 1998-06-10 | Daiichi Pharmaceutical Co., Ltd. | Taxol derivatives |
| US5977386A (en) | 1996-12-24 | 1999-11-02 | Bristol-Myers Squibb Company | 6-thio-substituted paclitaxels |
| UA55448C2 (uk) | 1997-04-28 | 2003-04-15 | Елі Ліллі Енд Компані | Стійка ліофілізована лікарська форма з активованим білком с (варіанти) та виріб, який її містить |
| WO1998056410A1 (en) | 1997-06-09 | 1998-12-17 | Childrens Hospital Los Angeles | Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence |
| US6991788B1 (en) | 1997-06-09 | 2006-01-31 | Childrens Hospital Los Angeles | Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence |
| IL133585A0 (en) | 1997-06-20 | 2001-04-30 | Baker Norton Pharma | Soluble prodrugs of paclitaxel |
| US7288665B1 (en) | 1997-08-18 | 2007-10-30 | Florida State University | Process for selective derivatization of taxanes |
| US5854051A (en) | 1997-09-15 | 1998-12-29 | Heska Corporation | Parasitic helminth asparaginase proteins, nucleic acid molecules, and uses thereof |
| JPH1192468A (ja) | 1997-09-17 | 1999-04-06 | Yakult Honsha Co Ltd | 新規なタキサン誘導体 |
| WO1999018113A1 (fr) | 1997-10-08 | 1999-04-15 | Bio Research Corporation Of Yokohama | Derives taxoides et leur procede de production |
| US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| WO1999048535A1 (en) | 1998-03-26 | 1999-09-30 | Schering Corporation | Formulations for protection of peg-interferon alpha conjugates |
| EP2921180B1 (en) | 1999-02-22 | 2019-08-14 | University of Connecticut | Albumin-free factor VIII formulations |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| AU2003213146A1 (en) | 2002-03-08 | 2003-09-22 | Eli Lilly And Company | Activated protein c formulations |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| EP1581582B2 (en) | 2003-01-06 | 2017-06-07 | Nektar Therapeutics | Thiol-selective water-soluble polmer derivatives |
| MX2009000284A (es) | 2006-06-30 | 2009-01-26 | Enzon Pharmaceuticals Inc | Hospedero recombinante para produccion de l-asparaginasa ii. |
| US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| EA018424B1 (ru) | 2007-04-20 | 2013-07-30 | ДСМ АйПи АССЕТС Б.В. | Варианты фермента аспарагиназы и их применение |
| FI20070455A0 (fi) | 2007-06-08 | 2007-06-08 | Reagena Ltd Oy | Menetelmä syöpäsairauksien tai tulehdussairauksien hoitoon |
| WO2011003633A1 (en) * | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
| NZ605873A (en) | 2010-06-25 | 2015-02-27 | Shire Human Genetic Therapies | Methods and compositions for cns delivery of arylsulfatase a |
| US9322008B2 (en) | 2010-09-01 | 2016-04-26 | Indian Institute Of Technology | Mutants of L-asparaginase |
| RU2441914C1 (ru) | 2010-10-06 | 2012-02-10 | Учреждение Российской академии медицинских наук Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича РАМН (ИБМХ РАМН) | Способ получения субстанции рекомбинантной l-аспарагиназы erwinia carotovora |
| CN102138909B (zh) | 2010-12-30 | 2013-03-13 | 常州千红生化制药股份有限公司 | 门冬酰胺酶冻干粉针剂及其制备方法以及门冬酰胺酶溶解液 |
| WO2013055699A1 (en) | 2011-10-10 | 2013-04-18 | Children's Hospital Los Angeles | Novel asparaginase and methods for treating diseases associated with asparagine dependence |
| CN102657852A (zh) * | 2012-05-22 | 2012-09-12 | 范铭琦 | 重组沃氏菌天门冬酰胺酶药物组合物及其制备法和应用 |
-
2017
- 2017-06-01 KR KR1020227042041A patent/KR102783452B1/ko active Active
- 2017-06-01 DK DK17831465.4T patent/DK3463308T4/da active
- 2017-06-01 RS RS20220190A patent/RS62979B2/sr unknown
- 2017-06-01 KR KR1020187037768A patent/KR102473887B1/ko active Active
- 2017-06-01 PT PT178314654T patent/PT3463308T/pt unknown
- 2017-06-01 FI FIEP17831465.4T patent/FI3463308T4/fi active
- 2017-06-01 AU AU2017299374A patent/AU2017299374B2/en active Active
- 2017-06-01 EP EP17831465.4A patent/EP3463308B2/en active Active
- 2017-06-01 HU HUE17831465A patent/HUE057856T2/hu unknown
- 2017-06-01 JP JP2019515776A patent/JP7109427B2/ja active Active
- 2017-06-01 KR KR1020237039742A patent/KR20230162139A/ko not_active Ceased
- 2017-06-01 UA UAA201812981A patent/UA123020C2/uk unknown
- 2017-06-01 MY MYPI2018002252A patent/MY198474A/en unknown
- 2017-06-01 SI SI201731078T patent/SI3463308T2/sl unknown
- 2017-06-01 MX MX2018014916A patent/MX388814B/es unknown
- 2017-06-01 CA CA3026070A patent/CA3026070A1/en active Pending
- 2017-06-01 SG SG11201810685WA patent/SG11201810685WA/en unknown
- 2017-06-01 WO PCT/US2017/035461 patent/WO2018017190A2/en not_active Ceased
- 2017-06-01 BR BR112018074823-4A patent/BR112018074823B1/pt active IP Right Grant
- 2017-06-01 SM SM20220049T patent/SMT202200049T1/it unknown
- 2017-06-01 US US16/306,302 patent/US12343387B2/en active Active
- 2017-06-01 IL IL263349A patent/IL263349B2/en unknown
- 2017-06-01 LT LTEPPCT/US2017/035461T patent/LT3463308T/lt unknown
- 2017-06-01 EP EP21211264.3A patent/EP4019007A1/en active Pending
- 2017-06-01 CN CN201780046796.6A patent/CN109640961B/zh active Active
- 2017-06-01 HR HRP20212027TT patent/HRP20212027T4/hr unknown
- 2017-06-01 ES ES17831465T patent/ES2905874T3/es active Active
- 2017-06-01 IL IL312621A patent/IL312621A/en unknown
- 2017-06-01 RU RU2018146395A patent/RU2758796C2/ru active
- 2017-06-01 PL PL17831465.4T patent/PL3463308T5/pl unknown
-
2018
- 2018-11-23 ZA ZA2018/07943A patent/ZA201807943B/en unknown
- 2018-11-29 PH PH12018502540A patent/PH12018502540A1/en unknown
- 2018-11-29 SA SA518400557A patent/SA518400557B1/ar unknown
- 2018-11-30 MX MX2021015544A patent/MX2021015544A/es unknown
- 2018-11-30 CL CL2018003418A patent/CL2018003418A1/es unknown
- 2018-12-18 CO CONC2018/0013753A patent/CO2018013753A2/es unknown
-
2022
- 2022-02-08 CY CY20221100106T patent/CY1124980T1/el unknown
- 2022-02-23 ZA ZA2022/02259A patent/ZA202202259B/en unknown
- 2022-03-01 JP JP2022030538A patent/JP2022071060A/ja active Pending
-
2023
- 2023-12-12 US US18/537,002 patent/US20240108701A1/en active Pending
-
2025
- 2025-01-17 US US19/029,699 patent/US20250242004A1/en active Pending
- 2025-10-28 JP JP2025181444A patent/JP2026016612A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022071060A5 (https=) | ||
| IL312621A (en) | Compositions of polyalkylene oxide-asparaginase and methods for their preparation and use | |
| Rodriguez et al. | Combination chemotherapy (" CHOP-Bleo") in advanced (non-Hodgkin) malignant lymphoma | |
| JP2021505661A5 (https=) | ||
| JP2019521179A5 (https=) | ||
| US11911467B2 (en) | Composition comprising PIC for treatment of cancer | |
| Friedenberg et al. | High‐dose dexamethasone for refractory or relapsing multiple myeloma | |
| Zinovieva et al. | Oncolytic vesicular stomatitis virus: optimisation strategies for Anti-Cancer therapies | |
| US7897159B2 (en) | Parapoxviruses in combination with classical cytotoxic chemotherapeutic agents as biochemotherapy for the treatment of cancer | |
| Mavroudis et al. | Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study | |
| Janka-Schaub et al. | Randomized comparison of rotational chemotherapy in high-risk acute lymphoblastic leukaemia of childhood—follow up after 9 years | |
| CN111658778A (zh) | 药物组合物及其制备方法与应用 | |
| McLeod et al. | Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency | |
| KR20230027279A (ko) | 화학요법-유발성 독성을 완화하기 위한 내피 세포 | |
| Nolen et al. | Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli | |
| WO2022265092A1 (ja) | がん治療用組成物 | |
| WO2023086796A3 (en) | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment | |
| Cieza‐Díaz et al. | Romidepsin in combination with low‐dose methotrexate in advanced‐stage mycosis fungoides and Sézary syndrome. | |
| US20220378879A1 (en) | Application of peg interferon and protooncogene product targeting inhibitor in synergistic treatment of renal carcinoma | |
| Chen et al. | Liposomal plasmid DNA encoding human thymosin α1 and interferon ω1 potently inhibits liver tumor growth in ICR mice | |
| NZ788906B2 (en) | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same | |
| Frytak et al. | Treatment toxicities in long-term survivors of limited small cell lung cancer | |
| JP2009091348A (ja) | がんの治療方法 | |
| CN100360173C (zh) | 甲硫氨酸酶在制备治疗卡氏肺囊虫感染的药物中的用途 | |
| US20240293352A1 (en) | Pharmaceutical compositions comprising vanadium salts |